A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea
CompletedOBSERVATIONAL
Enrollment
3,438
Participants
Timeline
Start Date
August 7, 2018
Primary Completion Date
May 25, 2023
Study Completion Date
May 25, 2023
Conditions
Essential Hypertension
Interventions
DRUG
Azilsartan Medoxomil
Azilsartan Medoxomil
Trial Locations (1)
10475
Myongji Hospital, Goyang-si
All Listed Sponsors
lead
Celltrion Pharm, Inc.
INDUSTRY
NCT04470817 - A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea | Biotech Hunter | Biotech Hunter